Email updates

Keep up to date with the latest news and content from BMC Medical Genomics and BioMed Central.

Open Access Technical advance

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use

Ryan van Laar1*, Rachel Flinchum1, Nathan Brown1, Joseph Ramsey1, Sam Riccitelli1, Christoph Heuck2, Bart Barlogie2 and John D Shaughnessy Jr1

Author Affiliations

1 Signal Genetics, 667 Madison Avenue, 14th Floor, New York, NY 10065, USA

2 University of Arkansas for Medical Sciences, Myeloma Institute for Research and Treatment, 4301 West Markham, Slot 816, Little Rock, AR 72205, USA

For all author emails, please log on.

BMC Medical Genomics 2014, 7:25  doi:10.1186/1755-8794-7-25

Published: 17 May 2014

Abstract

Background

Widespread adoption of genomic technologies in the management of heterogeneous indications, including Multiple Myeloma, has been hindered by concern over variation between published gene expression signatures, difficulty in physician interpretation and the challenge of obtaining sufficient genetic material from limited patient specimens.

Methods

Since 2006, the 70-gene prognostic signature, developed by the University of Arkansas for Medical Sciences (UAMS) has been applied to over 4,700 patients in studies performed in 4 countries and described in 17 peer-reviewed publications. Analysis of control sample and quality control data compiled over a 12-month period was performed.

Results

Over a 12 month period, the 70-gene prognosis score (range 0–100) of our multiple myeloma cell-line control sample had a standard deviation of 2.72 and a coefficient of variance of 0.03. The whole-genome microarray profile used to calculate a patient’s GEP70 score can be generated with as little as 15 ng of total RNA; approximately 30,000 CD-138+ plasma cells. Results from each GEP70 analysis are presented as either low (70-gene score <45.2) or high (≥45.2) risk for relapse (newly diagnosed setting) or shorter overall survival (relapse setting). A personalized and outcome-annotated gene expression heat map is provided to assist in the clinical interpretation of the result.

Conclusions

The 70-gene assay, commercialized under the name ‘MyPRS®’ (Myeloma Prognostic Risk Score) and performed in Signal Genetics’ CLIA-certified high throughput flow-cytometry and molecular profiling laboratory is a reproducible and standardized method of multiple myeloma prognostication.